Veera Motashaw, DO
Hospice and Palliative Medicine · Fishers, INNPI 1295171726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Merck at 35.3% of the total.
Across 15 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$95
- Genentech USA, Inc.$69
- Abbott$23
- Lilly USA, LLC$19
- Seagen Inc.$17
- Regeneron Healthcare Solutions, Inc.$17
- plus $28 from 2 others
What the payments were for
- Food & beverage$269100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $95 |
| Genentech USA, Inc. | 4 | $69 |
| Abbott | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Seagen Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Eisai Inc. | 1 | $13 |
How this compares
$269 in reported general payments places this provider in the 75th percentile of 32 hospice and palliative medicine providers in Indiana.
See all hospice and palliative medicine providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 61 | $44,047 |
| MovantikNaloxegol Oxalate | 21 | $8,806 |
| Fentanyl | 23 | $2,713 |
| Oxycodone Hcl | 78 | $1,363 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $1,019 |
| Morphine Sulfate ErMorphine Sulfate | 33 | $766 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $596 |
| Hydromorphone Hcl | 20 | $496 |
| Duloxetine Hcl | 16 | $411 |
| Mirtazapine | 23 | $340 |
| Gabapentin | 42 | $295 |
| Pregabalin | 15 | $257 |
| Haloperidol | 11 | $203 |
| Methadone Hcl | 13 | $140 |
| Alprazolam | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Fishers
- Tammy Durham-BoringFishers$158
- Ami PatelFishers$37
- Anoush JidarianAvon$5K
- Joseph McCollomFort Wayne$3K
- Angela WagnerIndianapolis$1K
- Lyle FettigIndianapolis$926
- Christina DrummondFort Wayne$458
- Lauren GnagyDanville$413
- Jaswinder JalfDanville$346
- Amy JohnsonIndianapolis$222
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.